ADVERTISEMENT

Dr. David Hohn, the former president of Roswell Park Cancer Institute, has been named chairman of Cleveland BioLabs, the Buffalo-based drug development company said.

Hohn, who has served on the Cleveland BioLabs board of directors for nearly two years, replaces the retiring Dr. Bernard Kasten, 65, who has been the company’s chairman for the past seven years.

The company also appointed two other directors: Julia Brown, a 40-year biotechnology industry executive who spent a quarter century at Eli Lilly & Co., and Anthony Prinicipi, a former Pfizer senior vice president who also served as U.S. secretary of veterans affairs from 2001 to 2005.

Michael Fonstein, Cleveland BioLabs’ president, who was replaced as CEO of the company last year by Yakov Kogan, also will retire from the board, effective at the company’s annual meeting, which likely will be held during June.